Drug Discovery World
NOVEMBER 29, 2023
Mapping individual Alzheimer’s disease progression The team’s model relies on clinical biomarkers for Alzheimer’s disease, including fluid markers for the amyloid protein that is responsible for plaque build-up in the brain, cognitive decline scores from pencil-and-paper testing, and MRI brain images.
Drug Discovery World
MARCH 7, 2023
She founded Neuroute in 2019, with the aim of empowering patients from diverse backgrounds to participate in drug trials. Other roles include Head of Biology at TopoTarget A/S, where she was responsible for the pre-clinical development of belinostat which went on to gain FDA approval to treat peripheral T-cell lymphoma.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
XTalks
APRIL 26, 2021
Related: After 18 Years, FDA Approves Malaria Prevention Drug. Given the success of Oxford’s Phase II trial, the study investigators are now gearing up for a Phase III licensure trial to assess large-scale safety and efficacy in 4,800 children aged 5 to 36 months across four countries in Africa.
Drug Discovery World
JANUARY 17, 2024
Moreover, NGS testing is being used in three main clinical circumstances, including: (i) the determination of patient eligibility for clinical trials, (ii) for guiding advanced refractory disease treatment when first line treatments have failed, and (iii) for off-label use of FDA-approved drugs.
Expert insights. Personalized for you.
52 
Let's personalize your content